Results 1 to 10 of about 17,658 (223)

Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis

Journal of International Medical Research, 2020
Objective This study compared the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) with conventional taxanes as neoadjuvant chemotherapy for breast cancer. Methods We searched the literature using PubMed, the Cochrane Library,
Yong Li, Xiaoju Lu, Qimou Lin, Weiwen Li
doaj   +1 more source

Distinct safety profiles of albumin-bound nab-paclitaxel and paclitaxel in pancreatic cancer focusing on hematologic and hepatobiliary risks

Scientific Reports
Nab-paclitaxel (albumin-bound paclitaxel) and traditional paclitaxel are both used in pancreatic cancer treatment, but their adverse event (AE) profiles may differ due to formulation differences.
Nan Qin, Zhongliu Bian, Jingtao Chen
doaj   +1 more source

Delayed hypersensitivity and cytokine release syndrome to paclitaxel and nab-paclitaxel: a case report [PDF]

Exploration of Asthma & Allergy
Hypersensitivity reactions (HSRs) to paclitaxel, particularly those mediated by the solubilizer Cremophor® EL, are common, occurring in approximately 10% of patients despite premedication.
Shaonie Ton-Leclerc, Florian Stehlin, Ana Maria Copaescu, Ghislaine Isabwe   +3 more
doaj   +1 more source

A five arm natural history study of nasal vestibulitis

Cancer Medicine, 2023
Introduction Nasal symptoms are frequently reported by patients undergoing chemotherapy. Methods Eligible patients planning to receive paclitaxel, docetaxel, nab‐paclitaxel, bevacizumab without a concomitant taxane, or “other” (non‐taxane, non ...
Elizabeth J. Cathcart‐Rake, David Zahrieh, Deanne Smith, Susan Young, Shaylene McCue, Amanda O'Connor, Stephan Thomé, Mario Lacouture, Terra Register, Jill Piens, Bret B. Friday, Charles L. Loprinzi   +11 more
doaj   +1 more source

Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer

International Journal of Nanomedicine, 2015
Liang Huang,1,2 Sheng Chen,1,2 Ling Yao,1,2 Guangyu Liu,1,2 Jiong Wu,1,2 Zhiming Shao1–3 1Department of Breast Surgery, Fudan University Shanghai Cancer Center/Cancer Institute, 2Department of Oncology, Shanghai Medical College, 3Institutes of ...
Huang L, Chen S, Yao L, Liu GY, Wu J, Shao ZM   +5 more
doaj  

Long-Term Continuation therapy with Nab-Paclitaxel and Bevacizumab ± Anti-PD-1 in Advanced NSCLC: Case Reports and Mechanistic Insights：case report

Case Reports in Oncology
Background. The role of nab-paclitaxel in non-small cell lung cancer (NSCLC) maintenance therapy remains underexplored, particularly in combination with anti-angiogenic agents and immunotherapy. We present two cases of advanced NSCLC achieving
Xiaofen Pan, Xueying Li, Jiehao Liao, Suhua Chen, Bo Wang   +4 more
doaj   +1 more source

Effect of intrapleural anti-Vascular Endothelial Growth Factor (VEGF) associated with nab paclitaxel in a murine model of malignant pleural effusion

BMC Cancer
Background Malignant pleural effusion (MPE) is a disease associated with poor prognosis, high morbidity, and significant mortality. Murine models of MPE have successfully replicated its formation and metastases, providing valuable insights into potential
Carlos Sergio Rocha Silva, Lisete Ribeiro Teixeira, Karina Rocha Pereira, Philippe Figueiredo Braga Colares, Vanessa Adelia Alvarenga, Roberta Karla Barbosa Sales, Amanda Cabral Roque, Evaldo Marchi, Ronei Luciano Mamoni, Milena Marques Pagliarelli Acencio   +9 more
doaj   +1 more source

Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting

Cancer Management and Research, 2017
Fadi Braiteh,1 Manish B Patel,2 Monika Parisi,2 Quanhong Ni,2 Siyeon Park,2,3 Claudio Faria2 1Comprehensive Cancer Centers of Nevada, University of Nevada School of Medicine, Las Vegas, NV, 2Celgene Corporation, Summit, NJ, 3The Ohio State University ...
Braiteh F, Patel MB, Parisi M, Ni Q, Park S, Faria C   +5 more
doaj  

2207

Journal of Clinical and Translational Science, 2017
OBJECTIVES/SPECIFIC AIMS: Patients with locally advanced pancreatic cancer typically have poor outcomes, with a median survival of ~16 months. Novel methods to improve local control are needed.
Jacob Ezra Shabason, Jerry Chen, Smith Apisarnthanarax, Nevena Damjanov, Bruce Giantonio, Arturo Loaiza-Bonilla, Peter O’Dwyer, Mark O’Hara, Kim Reiss, Ursina Teitelbaum, Paul Wissel, Jeffery Drebin, Charles Vollmer, Michael Kochman, Rosemarie Mick, Norge Vergara, Nirag Jhala, Abigail Berman, Jay Dorsey, Sydney M. Evans, Gary Kao, John N. Lukens, John P. Plastaras, James M. Metz, Edgar Ben-Josef   +24 more
doaj   +1 more source

FOLFIRINOX vs. gemcitabine/nab-paclitaxel for metastatic pancreatic cancer: A real-world study

Translational Oncology
Background: FOLFIRINOX and gemcitabine/nab-paclitaxel are widely used first-line regimens in metastatic pancreatic cancer (mPC); however, direct real-world comparisons and clear criteria for selecting between the two remain limited.
Jee Hoon Kim, See Young Lee, Galam Leem, Hee Seung Lee, Sung Ill Jang, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Seung Woo Park, Si Young Song, Jae Hee Cho, Jung Hyun Jo   +11 more
doaj   +1 more source